secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001999371-26-010226
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix shareholders approve reverse stock split authorization and 2026 equity plan at annual meeting
--------------------------------------------------------------------------------

- Reverse stock split authorized up to 1:250 ratio; 4,400,765 votes for, 2,826,586 against.
- 2026 Stock Incentive Plan approved; 2,019,646 for, 1,624,412 against, 3,504,257 broker non-votes.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2026; 6,910,516 votes for.
- Nine directors re-elected including CEO Seth Lederman; all nominees received >84% of votes cast.
- Shareholder turnout 54.22% (7,267,759 shares of 13.4M outstanding) on record date March 19, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/0001999371-26-010226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/tnxp-8k_050726.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-010226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer